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Olanzapine prevents the PCP-induced reduction in the neurite outgrowth of 
prefrontal cortical neurons via NRG1 
Abstract 
Accumulating evidence suggests that reducing neurite outgrowth and synaptic plasticity plays a critical 
role in the pathology of cognitive deficits in schizophrenia. The N-methyl-D-aspartate receptor antagonist 
phencyclidine (PCP) can induce symptoms of schizophrenia as well as reduce dendritic spine density and 
neurite growth. The antipsychotic drug olanzapine may improve these deficits. This study aimed to 
investigate: (1) if olanzapine prevents PCP-induced suppression of neurite outgrowth and synaptic protein 
expression; (2) if olanzapine affects the Akt-GSK3 signaling pathway; and (3) the role of neuregulin 1 
(NRG1) in this process. Immunofluorescence revealed that PCP treatment for 24 hours reduces both 
neurite length (28.5%) and the number of neurite branches (35.6%) in primary prefrontal cortical neuron 
cultures. PCP reduced protein and mRNA expressions of synaptophysin (24.9% and 23.2%, respectively) 
and PSD95 (31.5% and 21.4%, respectively), and the protein expression of p-Akt (26.7%) and p-GSK3β 
(35.2%). Olanzapine co-treatment prevented these PCP-induced effects in normal neurons but not in 
neurons from NRG1-knockout mice. These results indicate that NRG1 mediates the preventive effects of 
olanzapine on the PCP-induced impairment of neurite outgrowth and synaptic protein expression. This 
study provides potential targets for interventions on improving the efficacy of olanzapine on preventing 
cognitive deficits in schizophrenia. 
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Olanzapine Prevents the PCP-
induced Reduction in the Neurite 
Outgrowth of Prefrontal Cortical 
Neurons via NRG1
Qingsheng Zhang1,2, Yinghua Yu1,2,3 & Xu-Feng Huang1,2,3
Accumulating evidence suggests that reducing neurite outgrowth and synaptic plasticity plays a 
critical role in the pathology of cognitive deficits in schizophrenia. The N-methyl-D-aspartate receptor 
antagonist phencyclidine (PCP) can induce symptoms of schizophrenia as well as reduce dendritic spine 
density and neurite growth. The antipsychotic drug olanzapine may improve these deficits. This study 
aimed to investigate: (1) if olanzapine prevents PCP-induced suppression of neurite outgrowth and 
synaptic protein expression; (2) if olanzapine affects the Akt-GSK3 signaling pathway; and (3) the role 
of neuregulin 1 (NRG1) in this process. Immunofluorescence revealed that PCP treatment for 24 hours 
reduces both neurite length (28.5%) and the number of neurite branches (35.6%) in primary prefrontal 
cortical neuron cultures. PCP reduced protein and mRNA expressions of synaptophysin (24.9% and 
23.2%, respectively) and PSD95 (31.5% and 21.4%, respectively), and the protein expression of p-Akt 
(26.7%) and p-GSK3β (35.2%). Olanzapine co-treatment prevented these PCP-induced effects in normal 
neurons but not in neurons from NRG1-knockout mice. These results indicate that NRG1 mediates the 
preventive effects of olanzapine on the PCP-induced impairment of neurite outgrowth and synaptic 
protein expression. This study provides potential targets for interventions on improving the efficacy of 
olanzapine on preventing cognitive deficits in schizophrenia.
Schizophrenia is considered to be a neurodevelopmental disease1 with disturbances in synaptic connectivity 
being a key pathology2. While clinical evidence suggests that enlarged ventricles and decreased brain volume are 
the two most consistent structural abnormalities in schizophrenia3,4, rodent studies have found that these struc-
tural abnormalities are associated with abnormal neurite formation5,6. Moreover, shortened basilar dendrites and 
diminished dendrite collaterals at the prefrontal cortex (PFC) have been found in schizophrenia patients7–9. This 
suggests that neurite outgrowth and synaptic plasticity plays an important role in the pathology of schizophrenia, 
in particular relating to the cognitive deficit symptoms.
Phencyclidine (PCP), a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, can induce 
schizophrenia-like behaviors in humans and rodents10,11. Applications of NMDA receptor (NMDAR) inhib-
itors, including PCP, MK-801, and ketamine, induce disinhibition on pyramidal neurons, leads to the exces-
sive release of glutamate, and the full range of positive, negative and cognitive symptoms of schizophrenia in 
healthy humans12. Moreover, the effect of PCP on reducing dendritic spine density or neurite outgrowth has 
been reported in both in vitro13 and in vivo14 studies. However, the exact mechanism of PCP’s effect on neurite 
outgrowth is still unclear.
Olanzapine is a second-generation antipsychotic drug that has been reported to have some improvement 
effects on neurocognitive dysfunction in schizophrenia patients15–17. Along with other antipsychotics, olanzapine 
may also improve dendritic outgrowth and PSD95 and BDNF expression in hippocampal neuronal cultures18. 
Furthermore, the preventative effects of olanzapine on PCP-induced deficits in synaptic plasticity, pre-pulse 
inhibition, and cortical NMDAR expressions have also been reported in rodents19,20, suggesting a potential role 
of olanzapine in attenuating the cognitive dysfunctions in rodents, although the efficacies of this antipsychotic 
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in cognitive deficits in schizophrenia is still under debate21. Importantly, olanzapine’s ability to reverse the 
PCP-induced loss of spine synapses in rat PFC has also been reported22.
Neuregulin 1 (NRG1) is a trophic factor that signals by stimulating its tyrosine kinase receptor, ErbB4 (a 
type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors). It has been 
suggested that loss of function of NRG1 or ErbB4 causes deficits in the migration of pyramidal and GABAergic 
neurons, neurite outgrowth, and axon projection23, which is consistent with the ‘abnormal neural development’ 
model of schizophrenia. Interestingly, interactions between NRG1 and NMDAR have been suggested. It has been 
reported that NMDAR expression was reduced in NRG1 (∆TM)+ /− mice, and the phosphorylation of NR2B on 
Tyr1472, which is key to NMDAR’s channel property, was suppressed in NRG1 (∆TM)+ /− mice. These suggest 
that NRG1-ErbB4 may act downstream of NMDAR stimulation23.
We present evidence that olanzapine attenuates PCP’s inhibition effect on neurite outgrowth and synaptic 
plasticity, possibly through improving the PCP-induced downregulation of the NRG1 signaling pathway, and 
activating the downstream Akt-GSK cascade.
Results
PCP suppresses neurite outgrowth and synaptic protein expression. To examine the effect of 
PCP on neurite outgrowth and synaptic protein expression, we quantified neurite length and the number of 
branches (as markers for neurite outgrowth), and the expression of synaptophysin (pre-synaptic protein) and 
PDS-95 (post-synaptic protein) in primary PFC cultures treated with PCP or vehicle control for 24 h at DIV7. 
Immunofluorescence with MAP2 antibody revealed that PCP treatment significantly reduced both dendrite 
length (28.5%, p < 0.05) and the number of dendrite branches (35.6%, p < 0.05) in primary PFC cultures at DIV7 
(Fig. 1a–c). Western blotting revealed that the protein expression of synaptophysin and PSD95 were both down-
regulated by PCP treatment for 24.9% (p < 0.05) and 31.5% (p < 0.01), respectively (Fig. 1d–f). Consistently, 
Figure 1. PCP suppresses neurite growth and synaptic protein expression. (a–c) Immunofluorescence with 
MAP2 revealed that PCP treatment reduces neurite length and the number of neurite branches. (d–f) Protein 
expression of synaptophysin and PSD95 was downregulated by PCP treatment in PFC neurons on DIV7. (g,h) 
The mRNA expression of synaptophysin and PSD95 was reduced by PCP treatment in primary PFC neurons on 
DIV7. Error bars indicate SEM. *p < 0.05 vs control; **p < 0.01 vs control. n = 6/group.
www.nature.com/scientificreports/
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qRT-PCR revealed that the mRNA levels of synaptophysin and PSD95 were also reduced by PCP by 23.2% and 
21.4% (both p < 0.05), respectively (Fig. 1g,h).
PCP suppresses Akt-GSK signaling. Akt-GSK signaling has been reported to be an important intracel-
lular signal transduction pathway for NMDAR and NRG1’s effects on neurogenesis and synaptic plasticity24. To 
determine whether the Akt-GSK signaling cascade is affected by PCP in vitro, we examined the mRNA expres-
sions of TrkB and GSK3β as well as the protein expressions of Akt, p-Akt, GSK3β , and p-GSK3β in primary 
PFC cultures under PCP treatment. The phosphorylated Akt (p-Akt) and GSK3β (p-GSK3β ) protein expressions 
were both downregulated by PCP treatment compared to the control (− 26.7%, p < 0.05; and − 35.2%, p < 0.01, 
respectively), although PCP had no effect on total Akt or GSK3β expression (Fig. 2a,c,e). However, there was no 
difference between PCP and the control in the protein expression of total Akt and GSK3β (Fig. 2a,b,d), nor was 
mRNA expression of Akt or GSK3β (Fig. 2f,g).
Olanzapine prevents PCP-induced reduction in neurite outgrowth and synaptic protein 
expression. We investigated whether the co-treatment of olanzapine with PCP could prevent the reduc-
tion in neurite outgrowth and synaptic protein expression. Immunofluorescence with MAP2 revealed that 
olanzapine co-treatment inhibited the PCP-induced reduction in neurite length and the number of branches 
(Fig. 3a–c), while the olanzapine only group didn’t have significant difference compared to control (Fig. 3a–c). 
Western blotting revealed that while olanzapine only didn’t have an elevation effect compared to control, olan-
zapine co-treatment prevented the PCP-induced reduction in the protein expression of synaptophysin and 
PSD95 (Fig. 3d–f). Similarly, qRT-PCR revealed that olanzapine co-treatment also prevented the decrease in 
the mRNA levels of synaptophysin and PSD95 (Fig. 3g,h). These results indicate that olanzapine can prevent the 
PCP-induced reduction in neurite outgrowth and synaptic plasticity in primary PFC cultures.
Figure 2. PCP suppresses Akt-GSK signaling. (a–e) Protein expression of p-Akt and p-GSK3β was reduced by 
PCP treatment in PFC primary cultures on DIV7, while total Akt and total GSK3β expression was unchanged. 
(f,g) The mRNA expression of Akt and GSK3β was unchanged under PCP treatment. Error bars indicate SEM. 
*p < 0.05 vs control; **p < 0.01 vs control. n = 6/group.
www.nature.com/scientificreports/
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Olanzapine reverses the PCP-induced downregulation of Akt-GSK signaling. To investigate 
whether olanzapine co-treatment can reverse the PCP-induced down-regulation ofn Akt-GSK signaling in vitro, 
we examined the mRNA expressions of GSK3β and Akt, and the protein expressions of Akt, p-Akt, GSK3β , 
and p-GSK3β in primary PFC cultures under PCP treatment or Olanzapine-PCP co-treatment. As expected, 
olanzapine reversed the downregulation effect of PCP on phosphorylated Akt (p-Akt) and GSK3β (p-GSK3β ) 
protein expressions (Fig. 4a,c,e). However, the total Akt and GSK3β protein levels were not affected (Fig. 4a,b,d). 
Olanzapine did not affect the level of mRNA expression of Akt and GSK3β (Fig. 4f,g). These results suggest that 
the Akt-GSK cascade (particularly p-Akt and p-GSK3β expression), are downregulated by PCP treatment in vitro, 
but can be reversed by olanzapine.
Olanzapine does not change neurite outgrowth and synaptic plasticity in neurons from NRG1 
knockout mice. To examine whether NRG1 mediates olanzapine’s co-treatment effect on the PCP-induced 
reduction in neurite outgrowth and synaptic plasticity during neurodevelopment in vitro, we examined neurite 
growth and synaptic marker expression in primary PFC cultures taken from NRG1-KO mice at postnatal day 
0 (PN0), and treated with PCP or olanzapine-PCP co-treatment for 24 h at DIV7. Immunofluorescence with 
MAP2 showed that the Olanzapine-PCP co-treatment primary PFC cultures from NRG1-KO mice had reduced 
dendrite length and number of dendrite branches compared to those from wild-type mice (Fig. 5a–c). Moreover, 
western blotting showed a significant reduction in PSD95 and synaptophysin expression in the primary PFC 
cultures from the NRG1-KO mice compared to their wild-type counterparts (Fig. 5d–f). Olanzapine had no 
effect on PCP-induced reduction in the protein expression of synaptophysin or PSD95 in neuronal cultures from 
NRG1-KO mice (Fig. 5d–f). Consistently, qRT-PCR revealed that olanzapine had no effect on PCP-induced 
reduction in the mRNA expression of PSD95 and synaptophysin in PFC neuronal cultures from NRG1-KO mice 
(Fig. 5g,h). These results indicate that NRG1 signaling is important in mediating olanzapine’s effect in attenuating 
the PCP-induced reduction in neurite outgrowth and synaptic plasticity.
Olanzapine does not change PCP-induced downregulation of Akt-GSK signaling in primary PFC 
cultures from NRG1 knockout mice. Since olanzapine co-treatment reversed PCP’s effects on Akt-GSK 
signaling, we hypothesized that these effects may also be blocked in PFC cultures from NRG1-KO mice dur-
ing neurodevelopment. The protein expression of p-Akt and p-GSK was reduced in primary PFC cultures from 
Figure 3. Olanzapine inhibits the PCP-induced reduction in neurite outgrowth and synaptic protein 
expression. (a–c) Immunofluorescence with MAP2 revealed that olanzapine co-treatment prevented the 
PCP-induced reduction in neurite length and number of neurite branches. (d–f) Olanzapine co-treatment 
also inhibited the PCP-induced reduction in protein expression of synaptophysin and PSD95. (g,h) The PCP-
induced reduction in mRNA expression of synaptophysin and PSD95 was inhibited by olanzapine co-treatment. 
Error bars indicate SEM. *p < 0.05 vs control; **p < 0.01 vs control; #p < 0.05 vs PCP; ##p < 0.01 vs PCP. n =  
6/group.
www.nature.com/scientificreports/
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NRG1-KO mice compared to those from their wild-type littermates (Fig. 6a,c,e). However, in neurons from 
NRG1-knockout mice, the prevention effect of olanzapine on the PCP-induced reduction in p-Akt and p-GSK3 
expression disappeared (Fig. 6a,c,e), indicating that NRG1 is a critical mediator for the effect of olanzapine on 
preventing PCP-induced reduction in Akt-GSK signaling. Consistent with our previous findings, total Akt and 
GSK3β protein expression (Fig. 6a,b,d), and mRNA expression of Akt and GSK3β (Fig. 6f,g) was unchanged. 
Interestingly, immunofluorescence revealed that BDNF expression in NRG-KO mice primary PFC cultures com-
pared to wild-type was reduced by 31% (Fig. 7). Finally, the levels of p-Akt, p-GSK, and BDNF expressions were 
highly correlated with the PSD95 expressions across all treatment groups.
We further investigated the effect of PCP and olanzapine on the protein expression of endogenous NRG1. 
PCP treatment inhibited the NRG1 expression in primary PFC neurons (Fig. 8a,b), while olanzapine reversed this 
effect (Fig. 8c,d). In addition, the protein expression of NRG1 in NRG1-knockout mice was significantly lower 
than wild type mice neuronal cultures. No further reduction effect from PCP was evidenced (Fig. 8e,f). These 
results suggest that PCP and olanzapine may directly affect endogenous NRG1, leading to subsequent changes in 
downstream markers.
Discussion
In the present study, we found that 24 h PCP treatment suppressed neurite outgrowth and the expression of syn-
aptic proteins (PSD95 and synaptophysin) in PFC neuronal cultures. Moreover, PCP treatment also suppressed 
the Akt-GSK3 signaling pathway (downregulating the phosphorylation of Akt and GSK3β ), which may have 
led to the observed reduction in synaptic protein expression. These results are consistent with a previous report 
showing that PCP treatment decreases synaptic connectivity and synaptic protein expression in cultured cortical 
neurons, possibly via inhibiting BDNF secretion25. In addition, the role of Akt-GSK3 signaling in PCP-induced 
neurodegeneration has been demonstrated in primary neuronal cultures from the embryonic forebrains of 
Sprague-Dawley rats24. In the present study, PCP treatment decreased BDNF levels. In rodent cortical neurons, 
BDNF can activate phosphorylation of Akt, which could be inhibited by K252a (a TrkB inhibitor)26. It is possible 
that PCP treatment could inhibit BDNF secretion from PFC neurons, leading to the reduction of p-Akt and 
Figure 4. Olanzapine inhibits the PCP-induced suppression in Akt-GSK signaling. (a–e) Olanzapine co-
treatment eliminated PCP-induced reduction in the protein expression of p-Akt and p-GSK3β in PFC primary 
cultures on DIV7. (f,g) The mRNA expression of Akt and GSK3β was unchanged under both PCP treatment 
and olanzapine co-treatment. Error bars indicate SEM. *p < 0.05 vs control; #p < 0.05 vs PCP. n = 6/group.
www.nature.com/scientificreports/
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p-GSK3β expression. The suppressed Akt-GSK signaling may contribute to the suppression of neurite outgrowth 
and expression of synaptic proteins.
Olanzapine’s disinhibition effect on PCP-induced suppression in synaptic plasticity, pre-pulse inhibition, and 
cortical NMDAR expression has been evidenced in rodents19,20. Additionally, olanzapine could also improve den-
dritic outgrowth and PSD95 and BDNF expression in hippocampal neuronal cultures18. Therefore, in the present 
study, we examined the ability of olanzapine to prevent the PCP-induced suppression in neurite outgrowth and 
synaptic protein expression. We found for the first time at in primary PFC neurons during early developmental 
stage (DIV7), olanzapine can prevent PCP-induced reduction in neurite length and number of neurite branches. 
In addition PCP-induced downregulation in protein expressions of the presynaptic marker (synaptophysin) and 
the postsynaptic marker (PSD95) was also prevented by olanzapine treatment. Furthermore, olanzapine treat-
ment also prevented the PCP-induced downregulation in the Akt-GSK3 signaling of the PFC neurons.
The interaction between NMDAR and NRG1 is reciprocal. It has been suggested that NRG1-ErbB4 may act 
downstream of NMDAR stimulation23. However, in the study by Bjarnadottir et al. (2007)27, NRG1 signalling 
increases NR2B Y1472 phosphorylation and NMDAR function, while NRG1 (∆TM)+ /− mice had reduced 
NR2B Y1472 phosphorylation, suggesting NRG1/ErbB4 signalling may be upstream of NMDAR. Therefore, in 
the present study, we examined whether olanzapine can prevent the PCP-induced suppression in neurite out-
growth and synaptic protein expression in primary PFC neuronal cultures from NRG1 knockout mice com-
pared to wild-type mice. We found that in prefrontal cortical cultures of NRG1 knockout mice, olanzapine’s 
treatment effect on preventing PCP-induced reduction in neurite outgrowth and synaptic protein expression 
was eliminated. Consistently, the effect of olanzapine on preventing PCP-induced downregulation on Akt-GSK 
signaling pathway and the BDNF immunofluorescence expression was also diminished in PFC cultures from 
NRG1-KO mice. These results suggest that the intact NRG1 pathway is critical to olanzapine’s prevention effect on 
PCP-induced suppression in neurite outgrowth and synaptic plasticity. In addition, the reduced NRG1 induced 
by PCP may also contribute to a reduced NMDAR activity (possibly through the Fyn pathway)27, which in com-
bine with the blocking effect of PCP on NMDAR, leading to a further down-regulation of the downstream mark-
ers such as pAkt and pGSK (Fig. 9). We have examined the effect of olanzapine on NR2B Y1472 phosphorylation 
Figure 5. Olanzapine’s prevention effects on PCP-induced reduction in neurite outgrowth and synaptic 
protein expression were eliminated in neurons from NRG1-knockout mice. (a–c) The prevention effect of 
olanzapine on PCP-induced reduction in neurite length and neurite branches was blocked in neurons from 
NRG1-knockout mice. (d–f) The prevention effect of olanzapine on PCP-induced reduction in synaptophysin 
and PSD95 protein expression was blocked in neurons from NRG1-knockout mice. (f,g) The prevention effect 
of olanzapine on PCP-induced reduction in mRNA expression of synaptophysin and PSD95 was blocked in 
neurons from NRG1-knockout mice. Error bars indicate SEM. *p < 0.05 vs control; **p < 0.01 vs control; 
#p < 0.05 vs PCP; ##p < 0.01 vs PCP; ^p < 0.05 vs NRG1-control. n = 6/group.
www.nature.com/scientificreports/
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and Fyn Y420 phosphorylation with or without the Fyn autophosphorylation inhibitor PP2. We found that at the 
absence of PP2, olanzapine was able to up-regulate NR2B Y1472 phosphorylation as well as Fyn Y420 phospho-
rylation (See Supplementary Fig. S1 online). However, these effects were completely blocked by the Fyn autophos-
phorylation inhibitor PP2, indicating Fyn pathway is mediating the effect of olanzapine on upregulating NMDAR 
signaling, at least in the primary neuronal culture model of the present study.
Recently, studies have reported that the interaction between NRG1 and NMDAR28 and the activation of 
NMDAR facilitates neuronal development29. It is possible that the prevention effect of olanzapine on PCP-induced 
suppression in the Akt-GSK3 signaling pathway and neurite outgrowth was mediated through the NRG1-ErbB4 
pathway. In fact, the action of NRG1-ErbB4 has been suggested to be downstream of NMDAR stimulation23. 
Therefore, eliminating NRG1 from the neuronal cultures developed from NRG1-KO mice may block olanzap-
ine’s effect on the downstream Akt-GSK3 signaling and neurite outgrowth and synaptic protein expressions in 
non-mature neurons (DIV7), which relates to neuronal development. We further investigated the effect of PCP 
and olanzapine on the protein expression of endogenous NRG1, and found that PCP suppressed NRG1 pro-
tein expression, while olanzapine co-treatment reversed this effect. It is likely that PCP and olanzapine may act 
directly on endogenous NRG1 expression, leading to downstream changes in the Akt-GSK signaling pathway and 
neurite outgrowth and synaptic protein expressions.
According to the study by Bjarnadottir et al.27, clozapine can reverse the reduction of NR2B Y1472 phos-
phorylation induced by defects of NRG1 or ErbB4. However, in our study, olanzapine’s effect on correcting the 
PCP-induced downregulation of Akt-GSK signaling and neurite growth was eliminated by NRG1 knockout, 
indicating olanzapine’s effect is dependent on NRG1, while clozapine may correct the defected effect induced by 
NRG1 knockout, at least to some extent. Therefore, we suspect that olanzapine and clozapine may work on differ-
ent mechanisms on the NRG1 and NMDAR systems, which coincide with the differences in the pharmacological 
profiles. Future studies are required to confirm this hypothesis.
In conclusion, our results suggest that PCP (as an NMDAR antagonist) can suppress Akt (decreasing p-Akt) 
and activate GSK3β (decreasing p-GSK3β ), which may lead to the reduced expression of synaptic proteins 
(PSD95 and synaptophysin) and reduced neurite outgrowth in primary PFC neuronal cultures of wild-type 
mice. Olanzapine co-treatment can prevent these changes, possibly due to an elevated BDNF expression, hence 
Figure 6. Olanzapine’s prevention effects on PCP-induced downregulation in Akt-GSK3 signaling were 
eliminated in neurons from NRG1-knockout mice. (a–e) The prevention effect of olanzapine on PCP-induced 
reduction in p-Akt and p-GSK3β expression was blocked in neurons from NRG1-knockout mice. (f,g) The 
mRNA expression of Akt and GSK3β was unchanged. Error bars indicate SEM. *p < 0.05 vs control; #p < 0.05 vs 
PCP; ^p < 0.05 vs NRG1-control. n = 6/group.
www.nature.com/scientificreports/
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normalizing Akt-GSK3 signaling, synaptic protein expression, and neurite outgrowth. Finally, this normalization 
effect was diminished in PFC cultures collected from NRG1 knockout mice. This suggests that NRG1 signaling is 
at least partly responsible for olanzapine’s treatment effect on PCP-induced suppression of neurite outgrowth and 
synaptic protein expression. This is the first report to examine the effect of olanzapine in a combined model of 
schizophrenia (NRG1 knockout and PCP). Considering the clinical relevance of PCP-induced schizophrenia-like 
behaviors in humans and rodents10,11, our study may provide insights into the mechanism underlining olanzap-
ine’s effect on neurite outgrowth and synaptic protein expressions. While cautious should always be taken when 
extrapolating significance from primary cultures to in vivo or clinical studies, these results do provide interesting 
mechanistic insights for further studies.
Methods
Primary Cell Cultures. Experiments were run in 6 parallels and repeated for 3 times. Primary cortical cul-
tures from brain tissues of postnatal day 0 (PN0) wild-type (WT) and NRG1-knockout (KO) C57BL/6 mice were 
prepared as described previously30. All experimental procedures were approved by the Animal Ethics Committee, 
University of Wollongong, Australia, and complied with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes31. Briefly, dissociated cortical cells were plated at a final density of 5 × 105 cells/cm2, 
onto PDL-coated 24-well plates, containing neurobasal media (NBM) supplemented with B27. 5-FDU were 
added into the conditional medium (which was used to replace the NBM) to halt the growth of non-neuronal 
cells. Cultures were maintained at 37 ⁰C in a humidified CO2 incubator and used for experiments at 7 days in vitro 
(DIV7). Cells were treated with PCP at a final concentration of 1 μ M, and olanzapine at a final concentration of 
100 μ M for 24 hours. The concentration of PCP and duration of treatment was chosen based on a previous studies 
showing that 3 to 48 hours of PCP treatment at the concentration of 1 μ M can suppress intracellular signaling 
and synaptic protein expression25, while olanzapine at the dosage of 100 μ M may improve neurite length and 
branches18.
Western blot. After the PCP or olanzapine treatments, cells were harvested with lysis buffer (containing 
NP40, Protease Inhibitor Cocktail, 1 mM PMSF and 0.5 mM β -glycerophosphate). Total protein concentrations 
were determined by DC-Assay (Bio-Rad, Hercules, CA), and detected using a SpectraMax Plus384 absorbance 
microplate reader (Molecular Devices, Sunnyvale, CA). Samples were heat-treated in Laemmli buffer at 95 °C, 
loaded to 8% SDS-PAGE gels for fractionation, and then transferred onto Immun-BlotTM PVDF membranes 
(Bio-Rad, Hercules, CA). The block consists of 5% BSA in TBST. The membranes were then incubated with syn-
aptophysin, PSD95 (Life Technologies, NSW; dilution factor 1:1000), BDNF, NRG1 (Santa Cruz Biotechnology, 
Santa Cruz, CA; dilution factor 1:500), Akt, p-Akt, GSK3β , and p-GSK3β (Cell Signalling Technology, Beverly, 
Figure 7. The prevention effect of olanzapine on PCP-induced reduction in BDNF immunofluorescence 
intensity was eliminated in neurons from NRG1-knockout mice. Error bars indicate SEM. *p < 0.05 vs 
control; #p < 0.05 vs PCP. Scale bar: 5 μ m. n = 6/group.
www.nature.com/scientificreports/
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MA; dilution factor 1:1000) antibodies in TBST containing 1% BSA overnight at 4 °C. Secondary antibodies were 
anti-rabbit IgG conjugated with horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA; dilution 
factor 1:5000). For visualization, ECL detection reagents were used and films were exposed on the AGFA CP1000 
Tabletop Processor (AGFA Healthcarem Scoresby, VIC). Films were analysed using Quantity One software con-
nected to a GS-690 Imaging Densitometer (Bio-Rad, Hercules, CA).
Quantitative real-time PCR (qRT-PCR). The qRT-PCR protocol was adopted from our previous work32,33. 
Briefly, total RNA was extracted using the PureLink RNA extraction kit (Life Technologies, NSW) according 
to the manufacturer’s protocol. First-strand cDNA was synthesized with the VILO cDNA synthesis kit (Life 
Technologies, NSW) with 20 μ L reaction volume. qRT-PCR was carried out in triplicates using TaqMan Gene 
Expression Assays (Life Technologies, NSW) on LightCycler480+ (Roche, Penzberg, Germany). The endogenous 
control genes were selected using the geNormTM Reference Gene SelectionKit (Primerdesign, Southampton, UK). 
The results were normalized to mouse β -actin and GAPDH (cat. no. 4331182; Life Technologies, NSW), and 
were expressed as folds different from control. The assay identification of the target gene were Mm00436850_m1 
(synaptophysin), Mm00492193_m1 (PSD95), Mm01331626_m1 (Akt), and Mm00444911_m1 (GSK3b) (Life 
Technologies, NSW). The qPCR data was analysed using the “delta-delta Ct method”34 for comparing relative 
expression results between treatments. Experiments were performed in triplicate.
Immunofluorescence microscopy. Cells were grown to approximately 70% confluence on glass cover-
slips and treated with PCP, PCP + Olanzapine, or vehicle for 24 h before being fixed in 4% paraformaldehyde. 
Cells were then washed in PBS, and permeabilized with 0.3% Triton X-100 in PBS for 10 min. After blocking 
Figure 8. Effects of PCP and olanzapine on endogenous NRG1 expression. (a,b) PCP inhibits endogenous 
NRG1 protein expression. (c,d) Olanzapine reversed the inhibition effect of PCP on NRG1 protein expression. 
(e,f) No additional effect of PCP or olanzapine on NRG1 protein expression in neurons from NRG1-KO mice 
was evidenced in these neurons. Error bars indicate SEM. *p < 0.05 vs control; **p < 0.01 vs control; #p < 0.05 vs 
PCP. n = 6/group.
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the coverslips with 5% normal goat serum for 1 h at room temperature, primary antibody incubations were per-
formed in 1% goat serum in PBS overnight at 4 °C, followed by incubation in a secondary antibody cocktail of 
Alexa Fluor 488, 594, and DAPI (Life Technologies, NSW) for 2 h at room temperature. Cells were viewed using 
a 40× or a 63× oil immersion objective on a DMI6500B confocal microscope (Leica, Mannheim, Germany).
Statistics. SPSS (version 15; Chicago, IL) was used for statistical analysis. One-way analysis of variance 
(ANOVA) or two-way ANOVAs with post-hoc Tukey’s tests were performed for multiple comparisons. Data 
were expressed as mean ± SEM, and p < 0.05 was considered statistically significant.
References
1. Jaaro-Peled, H. et al. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation 
through Neuregulin-1–ErbB4 and DISC1. Trends Neurosci 32, 485–495, doi: 10.1016/j.tins.2009.05.007 (2009).
2. Hayashi-Takagi, A. & Sawa, A. Disturbed synaptic connectivity in schizophrenia: Convergence of genetic risk factors during 
neurodevelopment. Brain Res Bull 83, 140–146, doi: 10.1016/j.brainresbull.2010.04.007 (2010).
3. Woods, B. T., Ward, K. E. & Johnson, E. H. Meta-analysis of the time-course of brain volume reduction in schizophrenia: 
implications for pathogenesis and early treatment. Schizophr Res 73, 221–228, doi: 10.1016/j.schres.2004.05.014 (2005).
4. Wright, I. C. et al. Meta-Analysis of Regional Brain Volumes in Schizophrenia. Am J Psychiat 157, 16–25, doi: 10.1176/ajp.157.1.16 
(2000).
5. Badea, A., Nicholls, P. J., Johnson, G. A. & Wetsel, W. C. Neuroanatomical phenotypes in the Reeler mouse. NeuroImage 34, 
1363–1374, doi: 10.1016/j.neuroimage.2006.09.053 (2007).
6. Matricon, J. et al. Neuropathological and Reelin Deficiencies in the Hippocampal Formation of Rats Exposed to MAM; Differences 
and Similarities with Schizophrenia. PLoS One 5, e10291, doi: 10.1371/journal.pone.0010291 (2010).
7. Black, J. E. et al. Pathology of Layer V Pyramidal Neurons in the Prefrontal Cortex of Patients With Schizophrenia. Am J Psychiat 
161, 742–744, doi: 10.1176/appi.ajp.161.4.742 (2004).
8. Broadbelt, K., Byne, W. & Jones, L. B. Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial 
prefrontal cortex. Schizophr Res 58, 75–81, doi: 10.1016/s0920-9964(02)00201-3 (2002).
Figure 9. Proposed mechanism of PCP’s effect on NMDA-NRG1 interaction, synaptic protein production 
and neurite outgrowth. At the presence of PCP, NMDAR is blocked, which leads to an observed reduction of 
NRG1 expression. This reduction in NRG1 expression could be a positive feed-back effect from NMDAR to 
presynaptic NRG1 (an unknown mechanism), or could be a reduction in NRG1 production from the nucleus 
of the post-synaptic pyramidal neurons (further studies are required to confirm this). The reduction of NRG1 
then leads to reduction of NRG1-ErbB4 signalling, leading to a further reduction of NMDAR function, 
possibly via the Fyn pathway. The hypofunction of NMDAR and reduced NRG1 could then leads to reduced 
BDNF expression, and down-regulation of the downstream Akt-GSK phosphorylations. This finally leads to 
a reduction in synaptic protein productions , including synaptophysin and PSD95, also contributing to the 
reduction of neurite outgrowth as observed in the present study. Fyn: Proto-oncogene tyrosine-protein kinase; 
NR2: NMDA receptor subunit 2; SYN: synaptophysin.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:19581 | DOI: 10.1038/srep19581
9. Kalus, P., Bondzio, J., Federspiel, A., Müller, T. J. & Zuschratter, W. Cell-type specific alterations of cortical interneurons in 
schizophrenic patients. NeuroReport 13, 713–717 (2002).
10. Morris, B. J., Cochran, S. M. & Pratt, J. A. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5, 101–106, 
doi: 10.1016/j.coph.2004.08.008 (2005).
11. Coyle, J. Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis. Cell Mol Neurobiol 26, 363–382, doi: 10.1007/s10571-
006-9062-8 (2006).
12. Javitt, D. C. Glutamate and Schizophrenia: Phencyclidine, N-Methyl-d-Aspartate Receptors, and Dopamine-Glutamate Interactions. 
Int Rev Neurobiol 78, 69–108, doi: 10.1016/S0074-7742(06)78003-5 (2007).
13. Lee, E. et al. Effects of NMDA receptor inhibition by phencyclidine on the neuronal differentiation of PC12 cells. NeuroToxicology 
27, 558–566, doi: 10.1016/j.neuro.2006.02.006 (2006).
14. Hajszan, T., Leranth, C. & Roth, R. H. Subchronic Phencyclidine Treatment Decreases the Number of Dendritic Spine Synapses in 
the Rat Prefrontal Cortex. Biol Psychiat 60, 639–644, doi: 10.1016/j.biopsych.2006.03.015 (2006).
15. Keefe, R. E., Bilder, R. M., Davis, S. M. et al. Neurocognitive effects of antipsychotic medications in patients with chronic 
schizophrenia in the catie trial. Arch Gen Psychiat 64, 633–647, doi: 10.1001/archpsyc.64.6.633 (2007).
16. Keefe, R. S. E., Sweeney, J. A., Gu, H., Hamer, R. M. & et al. Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive 
Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. Am J Psychiat 164, 1061–1071 (2007).
17. Cuesta, M. J., Peralta, V. & Zarzuela, A. Effects of olanzapine and other antipsychotics on cognitive function in chronic 
schizophrenia: a longitudinal study. Schizophr Res 48, 17–28, doi: 10.1016/s0920-9964(00)00112-2 (2001).
18. Park, S. W. et al. Effects of antipsychotic drugs on the expression of synaptic proteins and dendritic outgrowth in hippocampal 
neuronal cultures. Synapse 67, 224–234, doi: 10.1002/syn.21634 (2013).
19. Anastasio, N. C. & Johnson, K. M. Atypical Antischizophrenic Drugs Prevent Changes in Cortical N-Methyl-D-Aspartate Receptors 
and Behavior Following Sub-chronic Phencyclidine Administration in Developing Rat Pups. Pharmacol Biochem Be 90, 569–577, 
doi: 10.1016/j.pbb.2008.04.017 (2008).
20. Amitai, N., Semenova, S. & Markou, A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by 
atypical antipsychotic medications in rats. Psychopharmacol 193, 521–537, doi: 10.1007/s00213-007-0808-x (2007).
21. Sacuiu, I., Chirita, V., Burlea, A. & Chirita, R. The effect of the atypical antipsychotics on cognitive deficit in schizophrenia. Int J 
Neuropsychoph 15, 61–61 (2012).
22. Elsworth, J. D., Morrow, B. A., Hajszan, T., Leranth, C. & Roth, R. H. Phencyclidine-induced Loss of Asymmetric Spine Synapses in 
Rodent Prefrontal Cortex is Reversed by Acute and Chronic Treatment with Olanzapine. Neuropsychopharmacol 36, 2054–2061 
(2011).
23. Mei, L. & Xiong, W.-C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosc 9, 437–452, doi: 
10.1038/nrn2392 (2008).
24. Lei, G., Xia, Y. & Johnson, K. M. The Role of Akt-GSK-3[beta] Signaling and Synaptic Strength in Phencyclidine-Induced 
Neurodegeneration. Neuropsychopharmacol 33, 1343–1353 (2008).
25. Adachi, N. et al. Phencyclidine-Induced Decrease of Synaptic Connectivity via Inhibition of BDNF Secretion in Cultured Cortical 
Neurons. Cereb Cortex 23, 847–858, doi: 10.1093/cercor/bhs074 (2013).
26. Zhang, Z. T., Fan, J., Ren, Y. X., Zhou, W. & Yin, G. Y. The release of glutamate from cortical neurons regulated by BDNF via the 
TrkB/Src/PLC-gamma 1 pathway. J Cell Biochem 114, 144–151, doi: 10.1002/jcb.24311 (2013).
27. Bjarnadottir, M. et al. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: Differential 
synaptic function in NRG1 (+ /− ) knock-outs compared with wild-type mice. J Neurosci 27, 4519–4529, doi: 10.1523/
Jneurosci.4314-06.2007 (2007).
28. Pandya, C. & Pillai, A. TrkB interacts with ErbB4 and regulates NRG1-induced NR2B phosphorylation in cortical neurons before 
synaptogenesis. Cell Commun Sigal 12, 47 (2014).
29. Villmann, C. & Becker, C.-M. On the Hypes and Falls in Neuroprotection: Targeting the NMDA Receptor. Neuroscientist 13, 
594–615, doi: 10.1177/1073858406296259 (2007).
30. Hilgenberg, L. G. W. & Smith, M. A. Preparation of Dissociated Mouse Cortical Neuron Cultures. JoVE 562, doi: 10.3791/562 (2007).
31. Australian Government National Health and Medical Research Council. Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes (seventh ed.) Canberra: Australian Government (2004).
32. Zhang, Q. et al. Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats. Prog Neuro-Psychoph 
51, 172–180, doi: 10.1016/j.pnpbp.2014.02.003 (2014).
33. Zhang, Q. et al. Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats. Int J 
Neuropsychopharmacol 17, 807–818, doi: 10.1017/S1461145713001697 (2014).
34. Livak, K. J. & Schmittgen, T. D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2− Δ Δ CT 
Method. Methods 25, 402–408, doi: 10.1006/meth.2001.1262 (2001).
Acknowledgements
This project was supported by the Schizophrenia Research Institute, Australia, using infrastructure funding from 
NSW Health. This study was funded by the Australian National Health and Medical Research Council. These 
funding sources had no role in the study design data analysis and interpretation, writing, or the decision to submit 
the manuscript for publication. The authors would like to thank Ms Linda Cohen for her editorial revision of the 
manuscript.
Author Contributions
X.-F.H. and Q.Z. designed and conducted the studies. Q.Z. analyzed the data and composed the first draft of the 
manuscript. Y.H., Q.Z. and X.-F.H. contributed to revisions of the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Zhang, Q. et al. Olanzapine Prevents the PCP-induced Reduction in the Neurite 
Outgrowth of Prefrontal Cortical Neurons via NRG1. Sci. Rep. 6, 19581; doi: 10.1038/srep19581 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
